Cargando…

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement

Efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement remain understudied. Here we analyzed the outcomes of CAR-T cell therapy in r/r DLBCL patients with CNS involveme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shumilov, Evgenii, Boyadzhiev, Hristo, Mazzeo, Paolo, Akhoundova, Dilara, Daskalakis, Michael, Novak, Urban, Lenz, Georg, Bacher, Ulrike, Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691788/ https://www.ncbi.nlm.nih.gov/pubmed/38044958 http://dx.doi.org/10.1097/HS9.0000000000000984

Ejemplares similares

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
por: Lakomy, Tim, et al.
Publicado: (2023)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study
por: Stoffel, Tanja, et al.
Publicado: (2022)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
por: Shumilov, Evgenii, et al.
Publicado: (2022)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

CAR T-cell therapy and critical care: A survival guide for medical emergency teams
por: Messmer, Anna S., et al.
Publicado: (2021)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment
por: von Matt, Stefanie, et al.
Publicado: (2023)

Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy
por: Gössi, Simona, et al.
Publicado: (2022)

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
por: Bacher, Ulrike, et al.
Publicado: (2018)

Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
por: Brechbühl, Simon, et al.
Publicado: (2021)

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
por: Seipel, Katja, et al.
Publicado: (2023)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
por: Messerli, Christian, et al.
Publicado: (2023)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

CNS Involvement of DLBCL Presenting with an Unusual Non-Enhancing Infiltrative Mass
por: Hsueh, Fu-Sheng, et al.
Publicado: (2023)

Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy
por: Sundriyal, Deepak, et al.
Publicado: (2020)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series
por: Flach, Johanna, et al.
Publicado: (2020)

S5-KL-1 CURRENT TREATMENT FOR DLBCL AND PROPHYLAXIS AND TREATMENT FOR SECONDARY CNS LYMPHOMA
por: Izutsu, Koji
Publicado: (2019)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland
por: Messmer, Anna Sarah, et al.
Publicado: (2021)

Regardless of personality, males show similar levels of plasticity in territory defense in a Neotropical poison frog
por: Peignier, Mélissa, et al.
Publicado: (2023)

Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes
por: Lim, Taekyu, et al.
Publicado: (2011)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
por: Nakagawa, Noriharu, et al.
Publicado: (2022)

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
por: Lamure, Sylvain, et al.
Publicado: (2021)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022)

CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response
por: Akhtar, Othman S., et al.
Publicado: (2023)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
por: Schnell, Bianca R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l9i9h7licf1r98u8ktdm6eko4g